National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 11) (No. PB 79 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L02023

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 79 of 2013
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 11)
 
National Health Act 1953
___________________________________________________________________________
 
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
 
Dated 27 November 2013
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor
Pharmaceutical Benefits Division
Department of Health
 
___________________________________________________________________
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No.11).
 
(2)                This Instrument may also be cited as PB 79 of 2013.
 
2             Commencement
                This Instrument commences on 1 December 2013.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]    Schedule 1 Part 1, entry for Ifosfamide:
omit:
 
Ifosfamide
Powder for I.V. injection 1 g in single dose vial
Injection
Holoxan
BX
MP
C1325 C1327
D

 
Powder for I.V. injection 2 g in single dose vial
Injection
Holoxan
BX
MP
C1325 C1327
D

insert:
 
Ifosfamide
Powder for I.V. injection 1 g
Injection
Holoxan
BX
MP
 
D

 
Powder for I.V. injection 2 g
Injection
Holoxan
BX
MP
 
D
 

 
[2]    Schedule 4, after the entry for Idarubicin:
omit:
 
Ifosfamide
C1325
 
Relapsed or refractory germ cell tumours following first‑line chemotherapy
 

 
C1327
 
Relapsed or refractory sarcomas following first‑line chemotherapy